Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Current Deferred Revenue (2020 - 2022)

Historic Current Deferred Revenue for GeneDx Holdings (WGS) over the last 3 years, with Q4 2022 value amounting to $40000.0.

  • GeneDx Holdings' Current Deferred Revenue fell 9154.33% to $40000.0 in Q4 2022 from the same period last year, while for Dec 2022 it was $40000.0, marking a year-over-year decrease of 9154.33%. This contributed to the annual value of $40000.0 for FY2022, which is 9154.33% down from last year.
  • GeneDx Holdings' Current Deferred Revenue amounted to $40000.0 in Q4 2022, which was down 9154.33% from $2.8 million recorded in Q3 2022.
  • GeneDx Holdings' Current Deferred Revenue's 5-year high stood at $3.8 million during Q1 2022, with a 5-year trough of $40000.0 in Q4 2022.
  • Moreover, its 3-year median value for Current Deferred Revenue was $2.8 million (2021), whereas its average is $2.1 million.
  • Over the last 5 years, GeneDx Holdings' Current Deferred Revenue had its largest YoY gain of 47281.95% in 2022, and its largest YoY loss of 9154.33% in 2022.
  • Over the past 3 years, GeneDx Holdings' Current Deferred Revenue (Quarter) stood at $3.8 million in 2020, then crashed by 87.59% to $473000.0 in 2021, then plummeted by 91.54% to $40000.0 in 2022.
  • Its Current Deferred Revenue stands at $40000.0 for Q4 2022, versus $2.8 million for Q3 2022 and $3.2 million for Q2 2022.